Aspire Biopharma Holdings (ASBP) Cash from Investing Activities Growth (1y) (2022)
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Cash from Investing Activities Growth (1y) (2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -46.27% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -388.99% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 90.55% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 91.53% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -41.67% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | -157.08% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -6,635.44% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | - |